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Abstract | Non-muscle-invasive bladder cancer (NMIBC), the most prevalent type of bladder 11 
cancer accounts for approximately 75% of bladder cancer diagnoses.  This disease has a 50% 12 
risk of recurrence and 20% risk of progression within 5 years , despite the use of intravesical 13 
adjuvant treatments (such as BCG or mitomycin C (MMC)) that are recommended by clinical 14 
guidelines. Intravesical  device-assisted therapies, such as radiofrequency-induced 15 
thermochemotherapeutic effect (RITE), conductive hyperthermic chemotherapy, and 16 
electromotive drug administration (EMDA), have shown promising efficacy. These device-17 
assisted treatments are an attractive alternative to BCG , as issues with supply has been a 18 
problem in some countries. RITE might be an effective treatment option in patients who have 19 
experienced BCG failure and are not candidates for radical cystectomy. Data from trials using 20 
EMDA suggest it is effective in high risk disease but require further validation and results of 21 
randomised trials are eagerly awaited for conductive hyperthermic chemotherapy. 22 
Considerable  heterogeneity in patient cohorts, treatment sessions, use of maintenance 23 
regimens, and single-arm study design makes it difficult to draw solid conclusions, although 24 
randomized controlled trials have been reported for RITE and EMDA.  25 
 26 
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[H1] Introduction  40 
Bladder cancer is the ninth most common cancer worldwide and is the thirteenth most 41 
common cause of cancer-associated mortality.1 Non-muscle-invasive bladder cancer 42 
(NMIBC) is the most frequently diagnosed type of bladder cancer; approximately 75% of 43 
bladder cancers are NMIBC.  The main stay of NMIBC management is by transurethral 44 
resection of bladder tumour (TURBT). NMIBC is stratified into low-risk, intermediate-risk, and 45 
high-risk categories using clinical and pathological factors. In the UK, intermediate-risk NMIBC 46 
is treated with adjuvant chemotherapy while high-risk NMIBC is treated with adjuvant 47 
immunotherapy.2 Neoadjuvant chemoablation has been described but is not standard of care 48 
within NMIBC guidelines due to limited level one evidence.3,4 49 
A single post-TURBT instillation of chemotherapy as adjuvant therapy within 24 hours, but 50 
ideally within 6 hours, reduces the relative risk of recurrence by 35%  (HR: 0.65, 95% CI 0.58-51 
0.74) in an individual patient data meta-analysis of low, intermediate and high-risk NMIBC.5 A 52 
course of intravesical chemotherapy is recommended for intermediate-risk NMIBC and 53 
reduces the relative risk of recurrence by 44% (HR: 0.56, 95% CI: 0.48-0.65).6 Mitomycin C 54 
(MMC) is the most commonly used intravesical chemotherapy.7. MMC is a cytotoxic antibiotic 55 
that induces cell death by alkylation and cross linking of DNA.8 Its molecular weight of 334 56 
kDa minimizes the risk of systemic absorption and toxic effects such as myelosuppression 57 
and pulmonary toxicity.8 Adverse events following intravesical delivery of MMC are 58 
predominantly local irritative voiding symptoms, which are reported in up to 39% of patients.9 59 
Evidence exists for alternative agents including gemcitabine, epirubicin, and Adriamycin, 60 
which have not been as commonly adopted as MMC due to less compelling evidence although 61 
recent studies have suggested that gemcitabine is efficacious and may be an alternative to 62 
MMC.10-12  63 
Intravesical BCG is recommended for high-risk NMIBC as a 6 once weekly  induction course 64 
followed by a maintenance regime of  3 once weekly instillations  at 3 and 6 months followed by 65 
every subsequent 6 months for up to 3 years.13 Maintenance BCG has been shown to increase 66 
absolute survival advantage by 5% at 5 years compared with induction BCG alone, supporting 67 
the use of maintenance treatment.13 However, up to 65% of patients treated with BCG report 68 
local toxicities  and 12% of patients do not complete maintenance therapy.14 Since 2012,  69 
availability of BCG has become an issue in some countries and the production of the 70 
Connaught strain is expected to cease in 2019 further limiting availability.15 Thus, the 71 
development of alternative intravesical treatments for bladder cancer is imperative.  72 
Despite use of adjuvant therapies, up to 52% of patients with high-risk NMIBC will have 73 
disease recurrence and 20% will progress to muscle-invasive bladder cancer (MIBC) within 5 74 
years.16 Radical cystectomy is the standard-of-care treatment after BCG failure, although 75 
rechallenging with further BCG remains an option according to National Comprehensive 76 
Cancer Network guidelines..2,17  77 
Developments for the treatment of NMIBC have focused on optimizing the delivery of 78 
established therapies or potentiating the effects of  chemotherapy using  intravesical  device-79 
assisted technology to deliver hyperthermia to the bladder wall or circulating chemotherapy 80 
and ionisation of chemotherapy to improve drug tissue penetration. The three most used 81 
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devices are radiofrequency-induced thermochemotherapeutic effect (RITE), conductive 82 
hyperthermic chemotherapy, and electromotive drug administration (EMDA) chemotherapy. 83 
Depot delivery devices, where slow releasing formulation of chemotherapy over an extended 84 
period of time, have been reported and are in early phase development.18,19 In this Review, 85 
we describe the evidence for intravesical  device-assisted technologies and summarize 86 
efficacy, safety, and tolerability outcomes. We also highlight other potential devices that are 87 
promising for the treatment of NMIBC.  88 
 89 
[H1] Hyperthermia as a treatment  90 
The use of hyperthermia to treat bladder cancer is based on the concept that heat can 91 
potentiate the effect of chemotherapy. 20  In vitro studies demonstrated that hyperthermia 92 
results in the denaturation of cytoplasmic structures and enzymatic proteins, inducing cell 93 
death by apoptosis and necrosis.21-23 Temperature elevation enhances cell membrane 94 
permeability resulting in increased drug absorption.24,25 Hyperthermia also causes the release 95 
of heat shock proteins (HSP), in particular HSP70, during cellular necrosis, which stimulates 96 
an adaptive T-cell response to induce the innate and adaptive immune system, despite 97 
promoting thermotolerance26,27. Furthermore, at 42°C exponential cell death seems to occur; 98 
above this temperature the benefit of hyperthermia might be minimal, but toxic effects  might 99 
become apparent.21 Cancer cells are more susceptible to hyperthermia than nonmalignant 100 
cells and, in clinical practice, hyperthermia is usually delivered at 42°C,  although 45°C has 101 
been described.28 Data from cell lines demonstrates synergism, whereby the effect of 102 
hyperthermia plus chemotherapy is greater than the combined additive effect.29,30 103 
Hyperthermia might also chemosensitize tumours to alkylating agents such as MMC via HSP 104 
mediated pathways.26  105 
In the clinical setting, hyperthermia has been used in combination with chemotherapy for the 106 
treatment of NMIBC.31,32 33  Hyperthermia can be either delivered by intravesical 107 
radiofrequency-induced hyperthermia or conductive heat via energy transfer from heated 108 
circulating fluid.31,32 33  Deep regional hyperthermia by radiofrequency is feasible and has been 109 
reported but is not in widespread use in clinical practice, although it might be effective in  MIBC 110 
as well as NMIBC.34   111 
  112 
[H1] RITE  113 
Radiofrequency-induced hyperthermia is an established therapy for a number of cancers 114 
including hepatocellular carcinoma,35 Barrett’s oesophagus,36 breast cancer37, and lung 115 
cancer.38 Radiofrequency is delivered to tissues with high perfusion and poor electrical and 116 
thermal conductivity at a frequency of 350-500 kHz for the treatment of localized  solid organ 117 
tumours.39,40  In contrast, RITE is delivered to the entire bladder at a frequency of 915 MHz 118 
using microwave which does not require conductive delivery of energy and penetrate low-119 
conductive tissues.40 This is ideal for the delivery of  heart  energy directly to the tissue to  120 
enable an efficient effect on the full bladder wall thickness . Pharmacokinetic analysis showed 121 
that RITE with 40 mg MMC over 60 minutes  resulted in >10-fold higher MMC concentration 122 
in bladder cancer tissue than passive intravesical MMC (median 665 ng/g versus 123 
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64 ng/g, P = 0.018).41 Plasma concentrations of MMC in patients treated using RITE plus MMC 124 
increased rapidly within 15 minutes and continued to increase and peak between 45 to 60 125 
minutes.42 In comparison, there was a dose response increase in patients treated with passive 126 
mitomycin and MMC plasma concentration peaks at 15 minutes and remained stable over 60 127 
minutes.42 In addition, a report by Ware et al.43 suggest that radiofrequency promotes the 128 
formation of tunnelling nanotubes within cancer cells, which might increase drug diffusion and 129 
increase efficiency.43 130 
RITE therapy for bladder cancer is the most established device-assisted therapy and the 131 
Synergo system was first reported in 1995.44 The Synergo system comprises a microwave 132 
radiofrequency source generating energy at 915 MHz from an antenna located at the tip of a 133 
Foley catheter (Fig. 1). The specialized triple lumen 18/20 Fr Foley catheter consists of the 134 
inflow and outflow lumen, the energy source antenna, and intravesical thermocouples at the 135 
catheter tip and proximal urethra that are used to monitor bladder wall temperature.44 The 136 
radiofrequency antenna delivers hyperthermia at 42 ± 2°C to the bladder wall by direct 137 
radiation, while the inflow and outflow channel recirculate  chemotherapy at room temperature 138 
(22ºC) within a closed system. 139 
Treatment comprises two 30-minute sessions; between each session  the bladder is emptied 140 
and a new solution of MMC is instilled, reducing the dilutional effect of diuresis.45 An adjuvant 141 
treatment protocol consists of two 30-minute sessions of 20 mg MMC instillations dissolved in 142 
40 ml of saline or water. An ablative protocol of two 30-minute sessions of 40 mg MMC in 40 143 
ml of saline or water is recommended in the manufacturer’s protocol.46 The requirement for 144 
intravesical administration of MMC midway of treatment session with RITE requires additional 145 
nursing input. An induction protocol of 6-8 once weekly treatments is administered followed 146 
by a maintenance protocol of one treatment every 6 weeks for the first year and one treatment 147 
every 8 weeks for the second year.47 An alternative protocol of six once weekly induction 148 
protocol with a maintenance protocol of three once weekly instillations at 3, 6, and 12 months 149 
has been reported.31 No comparisons between the two protocols because they have been 150 
used in different patient cohorts.   151 
 152 
[H2] Treatment efficacy  153 
To date, 21 reports from 20 studies on the efficacy of RITE for NMIBC have been published 154 
(Table 1); five studies report outcomes for RITE delivered in the pre-TURBT ablative 155 
setting,44,48-51 nine studies in the adjuvant setting47,52-60 and six studies had a mixture of  156 
patients treated with adjuvant therapy or pre-TURBT ablative treatment.61-66 Only four 157 
randomized controlled trials (RCTs) investigating RITE  have been conducted; three as 158 
adjuvant treatment47,53,56,60 and one in the ablative setting.50  159 
Reported recurrence free survival (RFS) differs between studies , reflecting the heterogenous 160 
patient cohorts, follow-up duration, and different treatment regimens and presence of CIS In 161 
studies including patients with papillary-only disease, RFS ranges from 53%–91% with 9.6–162 
24-month follow-up duration.47,53,58-60,65,66 However, in patients who had isolated or concurrent 163 
CIS (13–68%), RFS can range from 29%–88.6% at 14–38-months follow-up 164 
duration.47,54,55,57,61-64 A substantial number of patients treated with RITE  had developed 165 
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recurrence after previous intravesical therapy and disease progression occurs in 0–38% of 166 
patients. 47,49,52,53,55-65  167 
 168 
In the pre-TURBT ablative setting, data from nine studies reporting outcomes from 211 169 
patients suggest a complete response rate of 65.4%.44,48-51,62,63,65,66 Subsequent  studies have 170 
used an increased dose of MMC for ablative therapy (two 30-minute cycles of 40 mg MMC vs 171 
20 mg MMC), which might be beneficial for patients with widespread concurrent or isolated 172 
carcinoma in situ (CIS) .61,62 63-65 66 In one RCT of 52 patients, RITE resulted in significantly 173 
higher complete response rates than MMC alone (66% versus 22%, P< 0.01).50  174 
Three RCTs compared RITE with either passive MMC or BCG ; two trials in the setting of first-175 
line therapy and one in patients who had experienced BCG failure. Colombo et al.60 conducted 176 
a RCT involving 83 patients comparing RITE plus MMC  with passive MMC in intermediate-177 
risk or high-risk disease. Patients in both arms (42 RITE vs 41 passive MMC)  had complete 178 
TURBT followed by an induction schedule of 8 once weekly  intravesical instillations and a 179 
maintenance schedule of four once-monthly instillations. Patients in the RITE arm received 180 
two 30-minute sessions of MMC (20 mg in 40 ml saline) and patients in the passive MMC arm 181 
received 40 mg of MMC in 40 ml for 1 hour. At 24 months RFS was significantly improved in 182 
patients who received RITE (RITE: 82.9% versus passive MMC: 42.5%, P = 0.002) with no 183 
significant difference in disease progression between treatment arms.60 Subsequently, a 184 
longer-term follow-up of a median of 91 months suggested that the RFS superiority of RITE 185 
over passive MMC is sustained (RITE: 60% versus passive MMC: 20%, P <0.001).56  186 
Arends et al.31 later reported a RCT of 190 patients with intermediate-risk or high-risk NMIBC 187 
(92  RITE plus MMC vs 98  BCG). Patients in the RITE arm received a 6 once weekly  induction 188 
course of two 30-minute sessions of 20 mg  of MMC in 50 ml of water followed by a three once 189 
weekly  maintenance course at 3, 6, and 12 months, whereas patients in the BCG arm 190 
received full dose OncoTICE for 120 minutes per session for six once weekly induction 191 
instillations and three once weekly maintenance instillations at months 3, 6 and 12 months. 192 
The trial closed early owing to slow recruitment. Intention-to-treat results for the whole patient 193 
cohort were not reported. At the 24-month follow-up point, a trend towards significance in RFS  194 
was observed in the RITE arm (n = 71) compared with the control arm (n = 76) for patients 195 
with papillary-only disease (RITE: 78.1% versus 64.8%, P = 0.08). The per-protocol analysis 196 
suggested that the RFS was significantly higher  in the RITE arm than the BCG arm for patients 197 
with papillary disease (RITE: 81.8% versus BCG: 64.8%, P = 0.02). At 3 months, the complete 198 
response rate for patients with CIS was not significantly different between the two arms. This 199 
study was the first to compare RITE plus MMC with BCG therapy and, although the primary 200 
outcome was not met in the intention-to-treat analysis, the results suggest that RITE is an 201 
effective treatment for papillary NMIBC. These results are promising, but the outcomes for 202 
patients with CIS-only disease or concurrent CIS were not reported.  203 
Tan et al. 47 reported the results of the HYMN study, a multicentre phase III trial of 104 patients 204 
with intermediate-risk or high-risk NMIBC who developed recurrence after induction with or 205 
without maintenance BCG. Patients were randomized to RITE plus MMC or institutional 206 
standard practice. Patients in the RITE arm received 6 once weekly instillations of two 30-207 
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minute sessions of 20 mg MMC in 50 ml of sterile water as part of induction treatment and 208 
three once weekly instillations at months 3, 6, 12, 18 and 24 months as part of maintenance 209 
treatment. Institutional standard practice comprised either rechallenge with BCG (59%), 210 
passive MMC (18%), or EMDA with MMC (23%). At the 24-month follow-up point , no overall 211 
difference in intention-to-treat disease-free survival (DFS) was observed between the two 212 
treatment arms (HR 1.33; 95% CI: 0.84-2.10, P = 0.23) or in 3-month complete response rate 213 
in patients with CIS (RITE plus MMC arm: 30% versus control: 47%, P = 0.15). There was a 214 
non-significant higher intention-to-treat DFS in papillary-only disease (HR 0.50; 95% CI: 0.22-215 
1.17, P = 0.11) treated with RITE compared to control However, patients with CIS with/without 216 
papillary disease who received RITE had significantly higher disease recurrence than those 217 
who received treatment according to institutional standard practice (HR 2.06; 95% CI: 1.17-218 
3.62, P = 0.01), which resulted in the premature closure of the trial. A subsequent study 219 
reported an ablative protocol for patients with CIS comprising two 30-minute sessions of 40 220 
mg MMC.64  DFS in patients who received this protocol was 43% at a median of 22 months.64  221 
The requirement for an increased MMC dose in ablative setting might explain results observed 222 
in the HYMN study.  223 
The rate of disease progression in the HYMN trial was low (6%) at a median follow-up duration 224 
of 35 months, which should be compared with the 5% risk of 90-day mortality of radical 225 
cystectomy in these patients who have comorbidities.68 Despite limited RCT data, emerging 226 
evidence suggests that RITE plus MMC is a suitable alternative intravesical treatment option 227 
to passive MMC. Moreover, this modality could be considered for patients with high-risk 228 
papillary NMIBC as an alternative to BCG in the first-line setting.  Results following RITE plus 229 
MMC  treatment in patients with papillary-only disease who experienced BCG failure suggest 230 
this modality may be promising, but evidence is currently insufficient to support its use in 231 
patients with CIS. In fact, the FDA defined that a RFS of ≥25-30% at 18-24 months as clinically 232 
meaningful in BCG refectory patients.67 Both treatment arms in HYMN achieved a RFS >35% 233 
which was above the threshold for clinically meaningful effect although BCG failure patients 234 
recruited to HYMN had a better prognosis as BCG intolerant and relapsing patients were also 235 
included.   236 
 237 
[H2] Adverse events 238 
The reported adverse event rates following RITE suggest that it is well tolerated, with 92% of 239 
patients completing induction treatment.69 The most commonly reported adverse events 240 
during treatment are cystitis and/or storage lower urinary tract symptoms (LUTS) (32%), 241 
suprapubic pain (30%), and bladder spasm (20%).47,52,6144,50,51,55,57-60,62,65,66 Storage LUTS such 242 
as incontinence (12.6%) and nocturia (23.9%) and haematuria (17.2%) are  the most common 243 
adverse events after treatment and 3.3% of patients had urethral stricture (Table 2). However, 244 
most adverse events  are self-limiting and short lived.31,47  RITE recirculates room temperature 245 
MMC, hence, no thermal reaction to the urethra occurs which would theoretically minimise the 246 
risk of urethral strictures.70 Iatrogenic urethral injuries owing to catheter insertion might have 247 
contributed to the development of the urethral strictures reported. Thermal reaction on the 248 
posterior bladder wall, which is commonly observed following RITE treatment, can look 249 
suspicious for CIS owing to urothelium erythema and prompt unnecessary bladder biopsies 250 
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although they are benign and does not cause long term damage.44  Indeed, animal studies 251 
suggest that the  thermal reaction represent  focal oedema, haemorrhage, and oedema of the 252 
lamina propria and serosa, which resolves completely.71  253 
Adverse events reported in RCTs enable comparison of adverse event rates following RITE 254 
plus MMC or other standard-of-care treatment (Supplementary Table 1). RITE resulted in 255 
significantly more pain (P <0.001) and bladder wall erythema (P <0.001) than passive MMC, 256 
but no difference in dysuria, haematuria, urethral stenosis, or allergic reaction was observed.60 257 
Patients who received RITE plus MMC had a significantly increased risk of bladder pain during 258 
treatment (OR: 26.3; 95% CI, 14.3–48.5) or between treatments (OR: 1.6; 95% CI, 1.2–2.3), 259 
bladder spasms (OR: 15.5; 95% CI, 9.7–25.0), difficulty with catheterisation (OR: 16.7; 95% 260 
CI, 5.1–54.0), urethral strictures (OR: 2.3; 95% CI, 1.3–4.1), bladder wall erythema (OR: 5.8; 261 
95% CI, 4.0–8.3), and allergic reaction (OR: 2.7; 95% CI, 1.6–4.6) compared with BCG. 262 
However, significantly  less urinary frequency (OR: 0.61; 95% CI, 0.49–0.75), nocturia (OR: 263 
0.79; 95% CI, 0.63–0.98), incontinence (OR: 0.22; 95% CI, 0.12–0.37), haematuria (OR: 0.56; 264 
95% CI, 0.42–0.74), fever (OR: 0.09; 95% CI, 0.04–0.10), fatigue (OR: 0.17; 95% CI, 0.11–265 
0.28), and arthralgia (OR: 0.09; 95% CI, 0.03–0.31) were reported than for patients who 266 
received BCG.53  267 
In summary, RITE treatment for bladder cancer has been shown to be efficacious in 268 
intermediate or high risk papillary only BCG naïve NMIBC in a randomised setting. In the BCG 269 
failure setting, subgroup analysis of papillary only patients showed better efficacy in RITE 270 
treated patients compared to control, but this was not significant suggesting that this may be 271 
a treatment option in this patient cohort with limited options. There is limited data specifically 272 
in the BCG refractory setting and in patients with isolated or concurrent CIS disease and future 273 
planned trials will hopefully address this question. A single-arm study, RITE-Europe which will 274 
recruit patients with BCG-refractory CIS with or without papillary NMIBC is being planned . 275 
Treatment will consist of RITE with two 30-minute sessions of 40 mg MMC.  276 
 277 
[H1] Conductive hyperthermic chemotherapy 278 
Conductive hyperthermic chemotherapy is an alternative technology for delivering localized 279 
hyperthermia. The chemotherapy solution is externally heated and recirculated at a constant 280 
temperature via a catheter irrigation channel to deliver hyperthermia to the bladder wall by 281 
conduction.72  Previous to its application in the treatment of NMIBC, conductive hyperthermia 282 
was adopted as hyperthermic intraperitoneal chemotherapy (HIPEC), which is an approved 283 
treatment used in combination with cytoreductive surgery for peritoneal metastasis in ovarian, 284 
gastric, and colorectal cancer.73-75  285 
Two conductive hyperthermic chemotherapy systems for bladder cancer have been reported, 286 
both of which use MMC: the Combat Bladder Recirculating System (BRS)  and the Unithermia 287 
system. Minimal nursing ‘hands-on’ time is required once  the  system is  set-up as a mid-288 
treatment repeat instillation of MMC is not required compared to the RITE system allowing. 289 
This allows for a lower nurse to patient ratio when treatment is being administered.  The 290 
Combat BRS  system uses a 16 Fr three-way Foley catheter, which recirculates MMC in a 291 
close system with a bubble trap (Figure 2). MMC is heated to 43°C using an aluminium heat 292 
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exchanger that enables efficient heat transfer and accurate temperature control within ± 0.5 293 
°C. Each treatment uses 40 or 80 mg MMC in 50 ml of water for adjuvant and ablative 294 
treatment respectively recirculating for a continuous 60 minutes. 32,72,76 The Unithermia system 295 
uses a conical heat exchanger with a high recirculation rate to deliver hyperthermic MMC to 296 
the bladder via an 18 Fr Foley catheter. MMC is heated to 46.5 °C to deliver it at 44.5 °C to 297 
the bladder wall. The system is primed with 40 mg of MMC in 50 ml of water, which is 298 
recirculated for a continuous 50 minutes.33,76  Results of a pharmacokinetics study suggested 299 
that peak plasma MMC concentration is achieved around 45 minutes after MMC instillation.  300 
77  301 
Aqueous doxorubicin has been shown to efficacious for the treatment of NMIBC.78 The 302 
synergism between hyperthermia and temperature activated liposomes have been shown to  303 
enable a much higher dose of drug to be delivered at the target organ of treatment.79  304 
ThermoDox is a heat-activated liposomal encapsulation of doxorubicin that is a promising 305 
alternative to MMC. At 40-45°C; the liposomes release doxorubicin directly at the heated 306 
source, which enables a targeted approach.80  An in vivo study in pigs showed that intravenous 307 
ThermoDox with localized conductive hyperthermia delivered to the bladder resulted in the 10-308 
fold higher concentration of doxorubicin within the bladder than when ThermoDox was not 309 
heated or intravenous doxorubicin.80 Although heat-activated, ThermoDox is infused 310 
intravenously and patients with a history of cardiac disease  may  not be suitable candidates 311 
for this therapy owing to the cardiotoxic nature of doxorubicin although reports suggest that 312 
this is less apparent in the liposomal based formulation.81,82   313 
Five studies have reported results for conductive hyperthermia,32 72 76 33 83  and, although RCTs 314 
are in progress, level 1 evidence reporting outcomes for conductive hyperthermia for the 315 
treatment for NMIBC is lacking. 316 
 317 
[H2] Efficacy  318 
All reports to date are single-arm observational studies; two using the HIVEC system32,72 and 319 
three using the Unithermia system33,76,83, all of which use MMC (Table 3). All studies conducted 320 
to date included patients with predominantly intermediate-risk NMIBC and were proof-of-321 
concept studies with a limited sample size of between 15 and 43 patients. Studies using the 322 
HIVEC system report a RFS of 87.5% at the 24-month follow-up point in an adjuvant setting 323 
(n=16) 32  and a complete response rate of 60-63% after 8 once weekly  ablative intravesical 324 
treatments (n=39).32,72 The three studies using the Unithermia system included 117 patients 325 
and report RFS  of 65-70% at follow-up points between 24-41 months.33,76,83 These studies 326 
included one retrospective propensity score matched comparison83, which reported that BCG 327 
treated patients had a better RFS compared to  conductive hyperthermia (89.5% versus 328 
70.1%, P = 0.054).83 No difference in disease progression was reported. 329 
 330 
[H2] Adverse events 331 
Similar to RITE, conductive hyperthermia therapy is well tolerated and most adverse events 332 
are short lived (Table 4).86  Reliable adverse event data are available for the HIVEC system. 333 
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An interim analysis of adverse events in 307 patients recruited into HIVEC-I and HIVEC-II 334 
reported that 89% of patients completed a minimum of induction therapy compared with 95% 335 
of patients treated with passive MMC.86 In the patients treated with HIVEC, the most common 336 
adverse events were urinary frequency  (15%), suprapubic pain (13.1%), haematuria (11.8%), 337 
and urinary urgency  (11.8%).86  HIVEC was associated with significantly  increased incidence 338 
of urinary frequency (15.0% versus 5.8%, p=0.008), haematuria (11.8% versus 3.9%, 339 
p=0.010), and bladder spasm (6.5% versus 0.6%, p=0.006). No significant difference in grade 340 
III adverse events between HIVEC (2.3%) and passive MMC (1.5%) were observed, and these 341 
were predominantly caused by allergic reactions. No urethral strictures occurred in either 342 
treatment arm.86   343 
The safety and efficacy data for the Unithermia system is not well reported and at present the 344 
grade III adverse event rate is 12% (Table 5). Non-infective cystitis (37.2%) is the predominant 345 
reported adverse event followed by suprapubic pain (23.3%) and bladder spasm/ urinary 346 
urgency (22.1%).  Notably, one incidence of bladder perforation occurred following Unithermia 347 
treatment, resulting in a grade IV adverse event, which was reported by Ekin and colleagues.33 348 
Reasons for this remained uncertain but may be related to the higher circulation rate of fluid 349 
and temperature used.  350 
Prospective randomised data are eagerly awaited. HIVEC-I (EudraCT: 2013-002628-18)84 351 
and HIVEC-II (ISRCTN: 23639415) 85 are two multicentre, open-label, phase II RCTs recruiting 352 
patients from 12 Spanish and 13 UK centres respectively.. HIVEC-I will randomize 303 353 
patients with intermediate-risk disease to passive  MMC, conductive hyperthermic MMC for 354 
30 mins, or conductive hyperthermic MMC for 60 minutes.84  HIVEC-II will randomize 259 355 
patients with intermediate-risk disease to passive  MMC or conductive hyperthermic MMC for 356 
60 mins.85 Both studies have completed patient  recruitment at the end of 2017 and results 357 
are eagerly awaited.   358 
 [H1] EMDA MMC  359 
EMDA enhances the delivery of chemotherapy by electro-osmosis, iontophoresis, and 360 
electroporation whereby an electrical charge is generated between a catheter electrode and 361 
a cutaneous electrode to aid the transport of drug molecules into tissues.87,88 In vitro studies 362 
have shown that EMDA MMC delivers a sixfold greater concentration of MMC to the bladder 363 
wall than passive diffusion, reaching a peak concentration of MMC within 15 minutes of 364 
initiating treatment  .87,88 MMC was detected in all layers of the bladder wall in both treatments 365 
modalities; however, MMC concentration in the urothelium was 30 times greater using EMDA 366 
MMC than passive MMC, and threefold greater in the lamina propria and muscularis.87  367 
Intravesical EMDA MMC is administered using a battery-powered generator to deliver a 368 
controlled electric current of up to 30 mA.48 The electrical current passes between the 369 
intravesical active electrode at the tip of a catheter to a dispersive ground electrode positioned 370 
on the lower abdomen (Figure 3). The specialized 16 Fr catheter is in inserted and the bladder 371 
is washed with water, after which 40 mg MMC in 100 ml of water is instilled with the operating 372 
current maintained at 20 mA pulsed electrical current. Treatment time is 30 minutes per 373 
session, which is shorter than RITE and conductive hyperthermia and cadaveric studies 374 
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suggest that the peak concentration of MMC in the bladder wall is achieved after 15 minutes 375 
of initiating treatment.89 376 
 377 
[H2] Efficacy  378 
To date, seven studies have reported on the efficacy of EMDA MMC for bladder cancer, three 379 
of which investigated neoadjuvant EMDA MMC as monotherapy or in combination with 380 
BCG48,90,91 and a four studies in the adjuvant setting92-95 (Table 6). Four studies reported 381 
outcomes for monotherapy EMDA MMC,48,90,91,94,95 including one RCT in the neoadjuvant 382 
setting90 and one in the adjuvant setting.94  383 
Alternating BCG with EMDA MMC is a more established regimen than EMDA MMC as 384 
monotherapy, and promising results from a RCT and another single-arm study have been 385 
reported.92,93 Di Stasi et al. 93 randomized patients with high-risk NMIBC to either sequential 386 
BCG plus EMDA MMC or BCG alone. DFS was higher in the BCG plus EMDA MMC group 387 
than the BCG alone group at 88 months (58.1% versus 42.1%, P = 0.0012).93 Progression-388 
free survival (90.7% versus 78.1%, P = 0.004) and overall survival (78.5% versus 67.6%, P = 389 
0.045) were also significantly improved in BCG plus EMDA MMC cohort. However, the BCG 390 
plus EMDA MMC arm had an induction protocol of 9 once weekly treatment  compared with 391 
the 6 once weekly treatments  in the BCG alone arm and the increased number of induction 392 
treatments might have improved efficacy. A subsequent single-arm study using the same BCG 393 
plus EMDA MMC treatment regimen reported a 71% RFS and 95% PFS at 24 months.92 The 394 
proposed hypothesis for combination therapy is that instilling BCG first results in BCG-induced 395 
inflammation, which might increase urothelium permeability to MMC. The results for BCG plus 396 
EMDA MMC are impressive, but further validation is required before it is accepted as standard 397 
of care.  398 
In the monotherapy setting, a three-arm study randomized patients to either EMDA MMC, 399 
BCG, or passive MMC.94 Patients treated with EMDA MMC had a significantly longer time to 400 
recurrence than those who received passive MMC or BCG (EMDA MMC: 35 months versus 401 
MMC: 20 months versus BCG: 26 months, P = 0.013). However, no difference in time to 402 
disease progression was observed. Complete response rate at 6 months was higher in the 403 
EMDA MMC (58%) and BCG (64%) groups than in passive MMC group (31%) (P = 0.012). 404 
Di Stasi et al.90 reported outcomes of a trial in which patients were randomized to either 405 
TURBT alone, preoperative EMDA MMC followed by TURBT, or TURBT with a single 406 
postoperative instillation of passive MMC.90 At a median follow-up point of 86 months, patients 407 
in the preoperative EMDA MMC group had significantly higher RFS than those in the TURBT 408 
alone and TURBT with postoperative passive MMC groups (62% versus 36% versus 41%, P 409 
<0.0001).90 Colombo et al.48 compared ablative treatment with RITE, passive MMC, and 410 
EMDA MMC in a nonrandomized study, which showed that complete response rate was 66%, 411 
27.7%, and 40% respectively.48 412 
 413 
[H2] Adverse events 414 
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Similar to hyperthermia delivery systems, 90% of patients complete adjuvant induction 415 
treatment of EMDA MMC (Table 7). In a RCT comparing EMDA MMC, passive MMC, and 416 
BCG, significantly more local and systemic adverse events occurred in patients who received 417 
BCG than those in the two MMC arms.94 EMDA MMC had lower drug-related cystitis incidence 418 
(36% versus 67%, p=0.001), haematuria (22% versus 72%, p=0.001), frequency (19% versus 419 
58%, p=0.001), and fatigue (2.5% versus 44.4%, p=0.001) than BCG.94 Pooled adverse 420 
events from 73 patients suggest that drug related cystitis and/or storage LUTS (23%), bladder 421 
spasm (19%), and haematuria (12%) were the most common adverse events and no urethral 422 
strictures were reported.91,94,95 The most common reason for stopping EMDA MMC treatment 423 
was allergic reaction.93 Compared with RITE plus MMC , EMDA MMC has an increased rate 424 
of suprapubic pain and dysuria, and patients who received RITE patients experienced less 425 
urinary frequency .48 Anecdotally, subcutaneous burns have been reported to develop where 426 
the ground electrode pad is placed.  427 
No difference in reported adverse events were seen when sequential therapy of BCG-EMDA 428 
MMC was compared with BCG.93 Between 3% and 28% of patients treated with combination 429 
BCG and EMDA MMC could not tolerate the complete course of nine induction instillations.92,93 430 
LUTS, haematuria, and inability to tolerate catheter were the most frequent reasons for early 431 
termination of treatment.92  432 
Despite level one evidence reporting the superiority of EMDA, particularly when used in 433 
combination with BCG, compared to BCG and MMC, the use of EMDA has been limited in the 434 
treatment of NMIBC. A Cochrane review highlights that the quality of evidence in these studies 435 
were low and data on time to recurrence and progression as well as adverse events remains 436 
inconclusive suggesting that further studies are warranted.96  437 
[H1] Comparison of cost between treatments  438 
Comparison of the  estimated cost of treatment (disposables and drugs) between the different 439 
intravesical device assisted therapies based on end-user price suggest that that RITE 440 
treatment is the most costly followed by EMDA and conductive hyperthermia systems (Table 441 
8). Estimated cost of treatment was based on published treatment protocols. Cost of precuring 442 
the different devices itself as well as the service contract if applicable are normally the subject 443 
of separate negotiation and has not been reported herein. Physician and nurse cost to deliver 444 
treatment and other associated cost have been excluded.  445 
The disposables for the RITE and EMDA systems are more costly than those for conductive 446 
hyperthermic chemotherapy owing to the requirement of specialized catheters such as a 447 
radiofrequency antenna with thermocouples in the RITE catheter  or active electrode at the 448 
catheter tip in the EMDA catheter . The different maintenance protocols used between different 449 
treatment devices makes comparison of cost difficult. 450 
The only cost-effectiveness analysis that has been performed was reported in the RCT 451 
comparing BCG plus EMDA MMC with BCG alone.93 Based on a Markov model, sequential 452 
therapy was more costly than BCG therapy alone , but it was more efficacious  with a 5-year 453 
increment cost-effectiveness ratio (ICER) of  Can$27,815 per life-year gained (US$21,173, 454 
assuming Can$1=US$0.76).97 This figure is below the maximum acceptable ICER of £20,000-455 
£30,000 (US$26,472-US$39,709, assuming £1=US$1.32)  per quality-adjusted life-year 456 
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(QALY) used by the UK National Institute for Health and Care Excellence (NICE) and  the 457 
US$50,000 QALY used as a benchmark of acceptability when evaluating new technology.98,99   458 
 459 
[H1] Novel agents  460 
Several novel technologies have been reported and are at an early phase development. Two 461 
devices augment the cytotoxic effects of chemotherapy by prolonging exposure time. GemRIS 462 
is an intravesical gemcitabine depot delivery system (225 mg), which is constructed from 463 
silicone tubing and nitinol wire. 18  GemRIS is delivered into the bladder using an 18 Fr ureteric 464 
catheter-like inserter. The 5 cm-long device, which folds into a pretzel shape, remains in the 465 
bladder and releases gemcitabine by passive diffusion over a 7-day period (Figure 4).18   The 466 
device can be removed 7 days later by grasping forceps and flexible cystoscopy.18  In a phase 467 
1b study (NCT02722538) ,100 the GemRIS pretzel was well tolerated by all 10 patients with 468 
MIBC. Neoadjuvant GemRIS treatment for 14 days before radical cystectomy for all 10 469 
patients resulted in a reduction of tumour size in 80% of patients with 40% having pT0 disease 470 
after treatment.18  471 
VesiGel is a reverse-thermal gelation hydrogel compound combined with high-dose MMC that 472 
is liquid at room temperature and fully solidifies to a gel state at body temperature within 15 473 
minutes after instillation. VesiGel can be delivered using a standard Foley catheter and 474 
gradually dissolves over several hours while releasing MMC. This slow release preparation 475 
might be more effective than a single 1 hour instillation of aqueous MMC. In a study of 64 476 
patients with low-grade NMIBC treated with either VesiGel 0.06% (40 mg at 64 ml), VesiGel 477 
0.12% (80 mg at 64 ml), or MMC 0.1% (40 mg in 40 ml) as chemoablation therapy, VesiGel 478 
80 mg had a higher complete response  rate (87.5%) than aqueous MMC 40mg (63.6%) and 479 
VesiGel 40 mg (35.3%).19 The results of this proof-of-concept study are promising and future 480 
studies will be necessary to determine the effect of drug delivery and RFS in the adjuvant 481 
setting.19 Although results for VesiGel 80 mg are promising, interestingly, aqueous MMC 40 482 
mg had a better complete response rate than VesiGel 40 mg, suggesting that a slow-release 483 
formulation might take longer to reach peak chemotherapy concentration and this delay might 484 
negate the advantage of prolonged drug exposure, requiring an increased drug concentration. 485 
Early safety and tolerability data suggest that VesiGel is well tolerated with similar reports of 486 
allergic reaction to aqueous MMC, although the incidence of dysuria was higher (40% versus 487 
13%).101  488 
 489 
[H1] Conclusions 490 
Intravesical hyperthermia-inducing device-assisted therapies are attractive treatment options 491 
for augmenting the efficacy of intravesical chemotherapy for the treatment of NMIBC. 492 
Prospective randomized trials for RITE suggest that it might be superior to BCG in papillary 493 
only-disease both in the BCG-naive and BCG-failure cohorts. However, results remain 494 
inconclusive for patients with isolated CIS or papillary disease with concurrent CIS. RCTs 495 
comparing conductive hyperthermia plus MMC with passive MMC alone have reached their 496 
recruitment target and results are eagerly awaited  before adoption of intravesical device-497 
assisted therapies in clinical practice can be recommended. Results of RCTs of BCG-EMDA 498 
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MMC, both in the ablative (neoadjuvant)  and adjuvant setting, are impressive but this modality 499 
has not been widely adopted and will require further validation. Reported adverse events 500 
suggest that they are short lived and not significantly worse than intravesical BCG. Hence, 501 
these treatments are normally administered in a nurse-led environment. The induction regime 502 
of these treatments is now standardized to mirror traditional intravesical chemotherapy and 503 
BCG, but the maintenance treatment requirement and protocol has considerable variation. 504 
Other novel treatment options that increase intravesical chemotherapy contact time have 505 
shown promising results in phase I trials. With the issues with BCG supply in some countries 506 
the use of device-assisted therapies is expected to increase.  507 
 Key points  508 
• Intravesical chemotherapy and BCG is the recommended adjuvant treatment for non-509 
muscle-invasive bladder cancer (NMIBC) to reduce the risk of disease recurrence. 510 
• The combination BCG supply shortage and alternative bladder-sparing approaches in 511 
patients with BCG-refractory disease have led to the development of hyperthermia-512 
inducing device-assisted therapies for NMIBC. 513 
• Radiofrequency induced thermotherapy (RITE), hyperthermic conductive 514 
chemotherapy, and electromotive drug administration (EMDA) chemotherapy are the 515 
most widely used devices to augment intravesical chemotherapy. 516 
• Randomized controlled trials suggest that RITE and alternating BCG and EMDA 517 
mitomycin C is more efficacious than BCG alone . Data on patients with concurrent 518 
carcinoma in situ treated with RITE is currently inconclusive.  519 
•  Adverse events from RITE, hyperthermic conductive chemotherapy, and EMDA 520 
chemotherapy are short lived and better tolerated than BCG. 521 
• Other novel therapies that improve the delivery of chemotherapy by prolonging 522 
chemotherapy exposure time or targeted local therapy are promising.  523 
 524 
Review criteria  525 
A comprehensive literature review was performed using Medline Pubmed and Google 526 
Scholar. The following MESH words were used: ‘non-muscle invasive bladder cancer’, 527 
‘hyperthermia’, ‘chemohyperthermia’, ‘hyperthermia’, ‘radiofrequency induced thermotherapy’, 528 
‘RITE’, ‘EMDA’, ‘electromotive drug administration’, ‘mitomycin’, ‘MMC’, ‘intravesical 529 
chemotherapy’, ‘device assisted’ and ‘novel agents’. Original research, review articles, 530 
editorials, commentaries and letters to the editor which were in English were used for this 531 
review. The reference list of articles was screened to identify additional articles.  532 
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Tables  552 
Table 1: Overview of studies reporting outcomes using RITE for the treatment of NMIBC  553 
 554 
Study Patient 
entry 
Number of 
patients 
Risk group (previous 
intravesical treatment) 
Carcinoma in situ  Median follow up, 
months (Interquartile 
range ) 
Induction treatment 
details 
Maintenance  RFS and complete 
response rate 
(where specified) 
Progression-free 
survival 
Refs 
RCT of adjuvant RITE 
versus institutional 
standard practice  
2010- 2013  104: 
RITE: 48 
Control: 56 
Intermediate-risk (10%) or 
high-risk (90%) with 
recurrence following BCG, 
unwilling or unfit for 
cystectomy (previous 
intravesical treatment: 100%) 
68% 35.1 (23.1-44.5) RITE: 6 once weekly  
with 20 plus 20 mg 
MMC in 50 ml water for 
60 mins 
Control: 6 once weekly 
BCG in 50 ml saline or 
standard of care at 
institution (EMDA 
chemotherapy, 
gemcitabine, re-
challenge with MMC) 
RITE: 20 plus 20 mg 
MMC in 50 ml water 
once 6 weekly (year 
1) then once 8 weekly 
(year 2)  
Control: 3 weekly 
instillations at 3, 6, 
12, 18, and 24 
months 
Overall 2 year RFS: 
RITE: 34% 
Control: 32% 
(p=0.24) 
 
3 month CR: 
RITE: 30% 
Control: 47% 
(p=0.15)  
 
 
 
 
 
 
RITE: 83%  
Control: 87% 
47 
Single-arm adjuvant 
RITE  
2006- 2013 97 High-risk (previous intravesical 
treatment: 90.7%) 
75% 27 (16-47) 6-8 once weekly 40 mg 
MMC in 50 ml saline for 
60 mins 
 
20 mg MMC in 50 ml 
saline  6 once  weekly 
(year 1) then once 8 
weekly (year 2) 
NA 61.9% 52 
16 
 
RCT of adjuvant RITE 
versus BCG  
 
 
2002 - 2011 190: 
RITE: 92 
BCG: 98 
Intermediate-risk (69%) or 
high-risk (31%) risk BCG-naive 
(previous intravesical 
treatment: 11.1%)  
23% 24 (24) 
 
 
RITE: 6 once weekly 20 
plus 20 mg MMC in 50 
ml water for 60 mins  
 
BCG: 6 once weekly 
OncoTICE full dose for 2 
hours 
RITE: 20 plus 20 mg 
MMC in 50 ml  once 
weekly at 6 week 
intervals 
 
BCG: 3 once weekly 
at 3, 6, and 12 
months 
Papillary only RFS : 
RITE:81.8%, BCG: 
64.8% (p=0.08)  
 
 
CR for CIS at 3 
months: RITE: 
88.9%, BCG: 85.6% 
(p=1)  
 
 
RITE: 0% 
BCG: 1.4% 
53 
 
Single-arm adjuvant 
or ablative RITE  
 
2003-2009 21: 
11 ablative 
10 adjuvant 
Intermediate-risk or high-risk 
(>57%) recurrent NMIBC 
(previous intravesical 
treatment: 71%) 
38% 50 
(range: 1-120) 
Ablative: 12 once 
weekly 40 plus 40 mg 
MMC in 50 ml saline 
over 60 mins 
Adjuvant: 6 once weekly 
20 plus20 mg MMC in 
50 ml saline over 60 
mins 
NA 
 
 
Overall RFS: 29% Overall: 62% 61 
 
Single-arm adjuvant 
RITE 
NA 26 High-risk (previous intravesical 
treatment not recorded) 
23% 16.4 (6-48) 6 once weekly 20 plus 
20 mg in 50 ml saline for 
60 mins  
6 once monthly 20 
plus 20mg in 50 ml 
saline  
RFS: 88.4% NA 54 
Single-arm adjuvant 
RITE 
2006- 2010 42 High-risk (previous intravesical 
treatment: 64%) 
7% 38 (4-73) 4 once weekly then 6 
two weekly 40 plus 40 
mg of MMC in 50 ml 
water for 60 mins 
4 once monthly 40 
plus40 mg MMC in 50 
ml water 
RFS: 57.1% 88% 55 
17 
 
Single-arm adjuvant 
or ablative RITE  
 
2006- 2009 30: 
14 ablative 
16 adjuvant 
High risk (previous 
chemotherapy57%,  previous 
BCG 43%) 
13% Mean: 14±8.5 Ablative: 8 once weekly 
40 plus 40 mg MMC in 
50 ml water over 60 
mins 
Adjuvant: 6 once weekly 
20 plus 20 mg MMC in 
50 ml water over 60 
mins 
Ablative: 6 once 
monthly 40 plus 40 
mg MMC in 50 ml  
Adjuvant: 6 once 
monthly 20 plus 20 
mg MMC in 50 ml 
water  
 
Ablative CR: 42.9% 
Adjuvant RFS: 
43.8% 
Ablative: 82.4% 
Adjuvant: 0% 
 
62 
 
Single-arm adjuvant 
and ablative RITE  
2001-2011 92: 
26 ablative 
66 adjuvant  
Intermediate-risk (27%) or 
high-risk(73%) (previous 
intravesical treatment: 76%) 
28% 23 (range: 3- 84) Ablative: 8 once weekly 
40 plus 40 mg MMC in 
50ml water over 60 
mins 
Adjuvant: 6 once weekly 
20 plus 20 mg MMC in 
50 ml water over 60 
mins 
Adjuvant: 6 once 
every 6 weeks 20 plus 
20 mg MMC in 50 ml 
water 
Ablative CR: 79% 
Adjuvant RFS: 72% 
Ablative: NA 
Adjuvant: 95.3% 
63 
RCT of adjuvant RITE 
versus MMC 
1994-1999 83: 
RITE: 42 
MMC: 41 
Intermediate-risk and high-risk 
(>61%) (previous intravesical 
treatment: 58%)  
1.2% 91 (range: 6-154) 8 once weekly 20 plus 
20 mg MMC 50 ml 
water over 60 mins  
4 once monthly 20 
plus 20 mg MMC in 
50 ml water or 60 
mins 
RITE RFS:60%, 
MMC: 20% 
(p<0.001) 
 
RITE: 95.1% 
MMC: 92.9% 
56 
Single-arm adjuvant 
RITE 
2000-2007 56 High-risk  
(previous intravesical 
treatment: 43%, previous BCG: 
33.9%) 
16% 18 (range: 2-49) 6 once weekly 20 plus 
20 mg MMC over 60 
mins  
4-6 once weekly 20 
plus 20 mg MMC for 
6 treatments  
RFS: 64.7% 92.9% 57 
Single-arm adjuvant 
RITE 
2001-2008 111 High-risk papillary recurrence 
after BCG 
0% 16 (range: 2-74) 6 once weekly 20 plus 
20 mg MMC in 50 ml 
over 60 mins  
4-6 once weekly 20 
plus 20 mg MMC for 
6 treatments 
12 months RFS: 85% 
24 months RFS: 56% 
97% 58 
18 
 
Single-arm adjuvant 
or ablative RITE 
1997-2005 51: 
33 ablative 
18 adjuvant  
High-risk: CIS with or without 
papillary NMIBC (previous 
BCG: 66.7%) 
100% 22 (range: 3-77) Ablative (papillary lesion 
and/or wide-spread 
CIS): 8 once weekly 40 
plus 40 mg MMC in 
50ml water over 60 
mins  
Adjuvant: 6 once weekly 
20 plus 20 mg MMC in 
50 ml water over 60 
mins  
Ablative: 6 once 
monthly 40 plus 40 
mg MMC in 50 ml 
water  
Adjuvant: 6 once 
monthly 20 plus 20 
mg MMC in 50 ml 
water  
All-patient RFS: 55% 
 
All-patient CR at 4 
months: 92% 
 
90% 64 
Single-arm adjuvant 
or ablative RITE 
2000-2004 47: 
10 ablative 
22 adjuvant 
 
 
 
Intermediate-risk (16%) or 
high-risk(84%)   
(previous prophylactic BCG: 
59%; previous ablative BCG: 
80%) 
0% 9.6 Ablative: 8 onceweekly 
40 plus 40 mg MMC in 
50 ml water  
Adjuvant: 6-8 once 
weekly 20 plus 20 mg 
MMC in 50 ml water 
Ablative: 4 once 
monthly 40 plus 40 
mg MMC in 50 ml 
water  
Adjuvant:4-6 once 
monthly 20 plus 20 
mg MMC in 50 ml 
water  
Ablative CR: 80% 
Adjuvant RFS: 91% 
Ablative NA 
Adjuvant 0% 
65 
 
Adjuvant single arm 
RITE 
1994 -2003 90 Intermediate-risk (59%) or 
high-risk (41%) (previous BCG: 
46%) 
0% 18 (range: 4-24) Adjuvant: 6-8 once 
weekly 20 plus 20 mg in 
50 ml water 
Adjuvant: 4-6 once 
monthly treatments  
RFS: 84% 0% 59 
Single-arm adjuvant 
and ablative RITE  
 
NA 52: 
-28 ablative 
-24 adjuvant 
High-grade 0% 15.2 (range: 6-90), 
mean: 35.3 months 
Ablative: 8 once weekly 
40 plus 40 mg MMC in 
50 ml water over 40 
mins 
Adjuvant: 8 once weekly 
20 plus 20 mg MMC in 
50 ml water over 40 
mins 
Ablative: 4 once 
monthly 40 plus 40 
mg MMC in 50 ml 
water over 40 mins 
Adjuvant: 4 once 
monthly 20 plus 20 
mg MMC in 50 ml 
water over 40 mins 
Ablative CR: 75% 
 
Adjuvant RFS: 
62.5% 
 
NA 66 
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RCT of adjuvant RITE 
vs MMC 
1994-1999 83 (RITE: 42 
versus MMC: 
41) 
Intermediate-risk or high-risk 
(>61%) (previous intravesical 
treatment: 58%)  
1.2% 24 Both treatment arms: 
8 once weekly 20 plus 
20 mg MMC 50 ml 
water over 60 mins in 
both RITE and MMC 
arms  
Both treatment arms:  
4 monthly 20 plus 20 
mg MMC in 50 ml 
water over 60 mins  
RFS: RITE: 82.9% 
MMC: 42.5% 
(p=0.0002) 
 
RITE: 100% 
MMC: 97.6% 
60 
Single-arm ablative 
RITE 
 
1996-1998 80: 
29 RITE 
36 MMC 
15 EMDA  
Low-risk  0% 7-10 days after 
treatment 
All 4 once weekly: 
MMC: 40mg in 50 ml 
saline 
RITE: 40 mg in 50 ml 
water 
EMDA: 40 mg 150 ml 
water 
None CR: MMC: 27.7%, 
RITE: 66% 
EMDA: 40% 
NA 48 
Single-arm ablative 
RITE 
1992-1996 19 High-risk (previous intravesical 
treatment 100%)  
0% CR: 2 weeks after 
treatment 
8 once weekly 40 mg in 
40 ml water for 40 mins 
None CR: 47% 
 
100% 49 
RCT of ablative RITE 
versus MMC  
1989-1993 52: 
RITE: 29 
MMC: 23 
Intermediate-risk and high-risk 
(>7%) %) (previous intravesical 
treatment: 80.8%) 
0% 38  
36  
 
Both treatment arms:  
6-8 once weekly 40+40 
mg MMC in 50 ml water 
for 60 mins 
None E  
CR: RITE: 66%, 
MMC: 22% (p<0.01) 
 
RFS: RITE: 73%, 
MMC 61% (p>0.3) 
 
NA 50 
Single-arm ablative 
RITE 
1988 -1992 44 Intermediate-risk or high-risk 
(>27%)  (previous intravesical 
treatment: 63.6%) 
0% TURBT <3 weeks 8 twice weekly (within 6 
weeks) 30 mg MMC in 
60 ml water for 60 mins 
None CR: 70.4% NA 44 
Single-arm ablative 
RITE 
NA  12 Not known 0% TURBT 1-3 weeks 6-8 once weekly 30 mg 
MMC in 60 ml 
None CR: 41.7% NA 51  
CIS, carcinoma in situ; CR, complete response; DFS, disease-free survival; EMDA, electromotive drug administration; MMC, mitomycin C; NA, not applicable; NMIBC, non-555 
muscle-invasive bladder cancer; NS, not significant; RCT, randomized control trial; RITE, radiofrequency-induced thermochemotherapeutic effect; RFS, recurrence-free 556 
survival; TURBT, transurethral resection of bladder tumour;  557 
  558 
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Table 2 | Adverse events in patients with NMIBC treated with RITE  559 
First author  Number of 
patients 
Complete 
treatment 
(%)  
Grade ≥3 
adverse 
events (%) 
Haematuria 
(%) 
UTI or   
sepsis 
(%) 
Suprapubic 
pain (%) 
Non-
infective 
cystitis (%) 
Bladder 
spasmor  
urgency 
(%) 
Stricture 
(%) 
Allergic 
reaction 
(%) 
Incontinence 
(%) 
Nocturia 
(%) 
Reduced 
bladder 
capacity 
(%) 
Refs 
Tan et al., 2016  48 90 10 48 23 58 54 61 6 15 21 60 NR 47  
Sooriakumaran et 
al., 2016  
97 93 7 14 14 1 44 25 0 0 NR NR NR 52 
Kiss B et al., 2015 
61 
21 62 52 24 0 38 52 24 10 10 NR NR NR 61 
Maffezzini et al., 
2014 55 
42 88 0 62 0 29 71 12 0 0 29 NR NR 55 
Volpe et al., 2012  30 100 NR 27 7 3 23 30 0 13 NR NR 7 62 
Moskovitz et al., 
2012  
92 96 4 7 1 29 3 22 5 1 4 9 NR 63 
Halachmi et al., 
2011 57 
56 91 NR 4 00 13 18 23 2 12.5 NR NR NR 57 
Nativ et al., 2009 58 111 95 8 19 2 27 16 31 5 8 10 8 NR 58 
Moskovitz et al., 
2005  
47 NR   4 17 00 66 6 17 6 4 NR NR NR 65 
van der Heijden et 
al., 2004 59 
90 100 NR 9 00 37 24 0 4 9 NR NR NR 59 
Gofrit et al., 2004  52 96 NR 2 10 23 58 15 2 10 NR NR 10 66 
Colombo et al., 
2003  
42 69 NR 7 0 20 24 0 7 12 NR NR NR 60 
Colombo et al., 
1996  
29  93 NR NR NR NR 100 NR 0 NR NR 72 NR 50 
Colombo et al., 
1995  
44 NR  NR NR NR NR NR NR 2 2 NR NR NR 44 
Rigatti et al., 1991  12 NR NR NR NR 25% NR 42 0 NR NR NR NR 51  
Total  813 92.0 98.3 17.2 4.8 29.5 32.0 20.3 3.6 5.7 12.6 23.9 8.5 NA 
NMIBC, non-muscle-invasive bladder cancer; RITE, radiofrequency-induced thermochemotherapeutic effect; UTI, urinary tract infection. 560 
Note: Total percentages have been calculated by the sum of patients observing a specific adverse event divided by the total number of patients of each study where the specific adverse event 561 
is report    562 
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Table 3 | Outcomes of conductive hyperthermia for the treatment of NMIBC 563 
Setting Patient entry Number of 
patients 
Risk group Carcinoma in situ Median follow up, 
months (IQR) 
Induction treatment 
details 
Maintenance  RFS and complete 
response rate (where 
specified) 
Progression free 
survival 
Refs 
HIVEC           
Single-arm 
adjuvant or 
ablative  
 
2010 -2015 40:  
24 ablative 
16 adjuvant  
Intermediate-risk (35%) 
and high-risk (65%) 
(previous intravesical 
treatment: 73%) 
15% Ablative: 37 (95% CI: 
12-52) 
Adjuvant: 24 (95% CI: 
9-32) 
Ablative: 8 once 
weekly  80 mg in 50 
ml (43°C) in 50 ml 
water for 60 mins 
Adjuvant: 4 once 
weekly 40 mg in 50 
ml (43°C) 50 ml 
water for 60 mins 
Ablative: NA 
 
Adjuvant: 6 monthly 
40 mg in 50 ml  
Ablative:   
CR:62.5% 
48 month RFS: 79.2%  
 
Adjuvant: 
RFS: 87.5% 
NA 32 
Single-arm ablative  2010- 2011 15 Intermediate (27%) and 
high (73%) risk (73% 
previous intravesical 
treatment)  
0% TURBT 7-15 days 
after neoadjuvant 
treatment,  
 
29 months (95% CI: 
26-32) follow-up 
duration 
8 once weekly 80 mg 
in 50 ml water (43°C 
for 60 mins) 
NA CR: 60% 
 
RFS: 86.7% 
NA 72 
Unithermia           
Single-arm 
adjuvant  
2009- 2011 34 Low-risk, intermediate-
risk, or high-risk (24%) 
(all had recurrence 
after induction BCG) 
0%  41 6 once weekly 40 mg 
MMC in 50 ml saline 
(43-45°C) for 45 mins 
NA RFS: 64.7% 76.5% 76 
 
Single-arm 
adjuvant 
2011- 2013 43 Treatment-naive, high-
risk  
23% 30 (9-39) 6 once weekly 40 mg 
MMC in 50 ml of 
saline (43-45 C) for 
60 mins  
3 once weekly 
instillations at 3 and 6 
months  
RFS: 67.5% 
 
NA 33 
22 
 
Adjuvant 
propensity scored 
matched cohort 
(versus BCG) 
2004- 2014 182: 
CH: 40  
BCG: 142 
Treatment-naive, high-
risk  
18% 24 CH: 6 once weekly 40 
mg in 50 ml saline 
(43-45°C) for 60 mins 
BCG: 6 weekly 
CH: 3 once weekly 
instillations at 3 and 6 
months  
BCG: determined by 
clinician or  patient 
RFS: CH: 70.1%, BCG: 
89.5% 
(univariate: p=0.006, 
multivariate: 
p=0.054) 
 
CH: 87.2%  
BCG: 94.9% 
83 
CH, conductive hyperthermia; CR, complete response; DFS, disease-free survival; RFS, recurrence-free survival; MMC, mitomycin C; NA, not applicable; RFS, recurrence 564 
free survival; TURBT, transurethral resection of the bladder tumour. 565 
 566 
 567 
 568 
 569 
 570 
 571 
 572 
 573 
 574 
 575 
 576 
 577 
 578 
 579 
 580 
23 
 
Table 4: Adverse events in patients with NMIBC treated with conductive hyperthermia using HIVEC.   581 
First 
author  
Number of 
patients 
Complete 
treatment (%) 
 
Grade ≥ 3 
adverse 
events (%) 
Haematuria (%) UTI or 
sepsis (%) 
Suprapubic pain 
(%) 
Non-
infective 
cystitis (%) 
Bladder 
spasm or 
urgency (%) 
Stricture (%) Allergic 
reaction (%) 
Urinary 
retention (%) 
Bladder 
calcification (%) 
Refs 
Sousa et 
al., 2016  
40 98 8 23 23 28 40 33 3 3 8 3 32 
Sousa et 
al., 2014  
15 NR  20 13 27 33 27 0 7 0 7 72 
Total  55 98 5.5 21.8 20.0 27.3 38.2 30.9 1.8 3.6 5.5 3.6 NA 
NA, not applicable; NMIBC, non-muscle-invasive bladder cancer; NR, not reported; UTI, urinary tract infection. 582 
Note: Total percentages have been calculated by the sum of patients observing a specific adverse event divided by the total number of patients of each study where the specific adverse event 583 
is report    584 
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Table 5 | Adverse events in patients with NMIBC treated with conductive hyperthermia using Unithermia. 585 
First author  Number of 
patients 
Complete 
treatment 
(%)  
Grade ≥ 3 
AE 
(%) 
Haematuria 
(%) 
UTI or 
sepsis 
(%) 
Suprapubic 
pain 
(%) 
Non-
infective 
cystitis 
(%) 
Bladder 
spasm or 
urgency 
(%) 
Stricture 
(%) 
Allergic 
reaction 
(%) 
Incontinence 
(%) 
Frequency 
(%) 
Bladder 
perforation 
(%) 
Refs 
Soria et al., 
2016  
34 88 12 NR 4 NR NR 24 NR 6 3 15 0 76 
Ekin et al., 
2015  
43 93 12 9 0 23 37 21 0 7 2 26 2 33 
Ekin et al., 
2015  
40 95 NR  NR NR NR NR NR NR NR NR NR NR 83 
Total  117 94.0 11.7 9.3 3.9 23.3 37.2 22.1 0 6.5 2.6 20.8 1.3 NA 
NA, not applicable; NMIBC, non-muscle-invasive bladder cancer; NR, not reported; UTI, urinary tract infection. 586 
 Note: Total percentages have been calculated by the sum of patients observing a specific adverse event divided by the total number of patients of each study where the specific adverse event 587 
is report   588 
  589 
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Table 6: Outcomes using EMDA MMC as monotherapy or in combination with BCG for the treatment of NMIBC 590 
Setting Patient entry Number of patients Risk group Carcinoma 
in situ 
Median follow 
up, months (IQR) 
Induction treatment 
details 
Maintenance  RFS and complete 
response rate 
(where specified) 
Progression-free 
survival 
Refs 
Single-arm adjuvant 
sequential BCG and  
EMDA MMC 
2009- 2013 107 New or recurrent 
high-risk  
32% 24 BCG weekly for week 1 
and 2 plus EMDA MMC 
(40 mg and 20 mA for 
30 mins) for week 3. 
This was repeated 
three times. 
3 once weekly BCG 3 
months after 
induction and every 6 
months for 3 years.  
RFS: 68% 3% 92  
RCT of TURBT versus 
TUBRT plus immediate 
postoperative MMC 
(adjuvant) versus 
neoadjuvant EMDA 
MMC plus TURBT 
1994- 2003 374: 
124 TURBT 
126 TUBRT plus 
immediate 
postoperative MMC 
124 neoadjuvant 
EMDA MMC plus 
TURBT 
Low-risk (6%), 
intermediate-risk 
(66%),or high-risk 
(28%) (no previously 
intravesical 
treatment)  
0% 86 (57-125) TURBT alone  
TURBT plus immediate 
postoperative MMC 40 
mg MMC in 50 ml 
water (60 minutes)  
Neoadjuvant EMDA 
plus TURBT 40 mg 
MMC in 100 ml water 
(20 mA for 30 mins). 
All groups  
Intermediate-risk: 6 
once weekly40 mg 
MMC in 50 ml water  
 
High-risk: 6 once 
weekly 81 mg BCG 
(ImmuCyst) in 50 ml 
saline for 120 mins 
RFS: TURBT: 36%, 
TURBT plus MMC: 
41%, 
Neoadjuvant EMDA 
MMC plus  TURBT: 
62% (p≤0.0001) 
 
PFS TURBT: 79% 
TURBT plus MMC: 
81% 
Neoadjuvant EMDA 
MMC plus TURBT: 
94% 
 
90 
RCT of adjuvant BCG 
versus BCG and EMDA 
 
 
1994- 2002 212: 
105 BCG 
107 BCG and EMDA 
 
High-risk- all pT1 
(previous intravesical 
treatment: 42%)  
27% 88 (63-110) BCG alone: 81 mg BCG 
over 120 mins weekly 
for 6 once weeks  
 
BCG and EMDA: 81 mg 
BCG over 120 mins 
weekly for 2 weeks 
then 40 mg EMDA (20 
mA for 30 mins) 
weekly repeated 3 
times (9 instillations in 
total) plus 
maintenance  
BCG alone: once 
monthly for 10 
months 
 
BCG and EMDA: 40 mg 
EMDA monthly for 2 
months then 81 mg 
BCG for month 3. 
Repeated for three 
cycles 
RFS: 
BCG alone: 42.1%, 
BCG plus EMDA: 
58.1% (p=0.0012) 
 
PFS: BCG alone: 
78.1%,  
BCG and EMDA: 
90.7% (p=0.004) 
 
OS: BCG alone: 
67.6%, BCG and 
EMDA: 78.5% 
(p=0.045) 
 
CSS: BCG alone: 
89.4%, BCG and 
EMDA: 94.4% 
(p=0.01)  
93 
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RCT of adjuvant EMDA 
MMC versus MMC 
alone versus BCG 
1994- 2001 108: 
36 EMDA MMC 
36 MMC 
36 BCG  
High-risk CIS ± pT1 
(previous intravesical 
treatment not 
specified) 
100% 6 (6) All: 6 once weekly: 
 EMDA MMC 40 mg 
(20 mA) in 100 ml 
water for 30 mins  
 
 
MMC: 40 mg in 100 ml 
water for 60 mins 
BCG: 81 mg in 50 ml 
saline for 120 mins. 
 
All: 10 monthly 
instillations if 
response  
 
Non-responders at 3 
months re-challenged 
with another 6 weeks 
induction.  
Time to recurrence:  
EMDA MMC: 
6 month, 
MMC alone: 20 
months, BCG: 26 
months, (p=0.013) 
 
CR: EMDA MMC: 
58%, MMC alone: 
31%, BCG: 
64%(p=0.012) 
 
  
No difference in 
progression 
94 
Ablative non-
randomized 
comparative study of 
RITE, MMC, and EMDA 
MMC 
1996- 1998 80: 
29 RITE 
36 MMC  
15 EMDA  
Low-risk  NA 7-10 days after 
treatment 
All: 4 once weekly: 
MMC 40mg in 50 ml 
saline for 60 mins 
RITE: 40 mg MMC in 
50 ml water (42.5C) 
for 60 mins 
EMDA MMC: 40 mg 
MMC (20 mA) in 150 
ml water for 20 mins 
NA CR  
MMC: 27.7%  
RITE: 66%, 
EMDA: 40% 
NA 48 
Single-arm adjuvant 
EMDA MMC  
NA 22 EMDA MMC Low-risk (5%), 
intermediate-risk 
(67%), or high-risk 
(28%) (previous 
intravesical treatment 
not specified) 
9% 14.1 4 once weekly EMDA 
MMC 40 mg in 100 ml 
saline (15 mA) for 20 
mins 
NA RFS: 56.3% NA  95 
Non-randomized 
comparison study of 
adjuvant EMDA MMC 
versus MMC  
 
1993- 1995 28: 
13 MMC 
15 EMDA MMC 
Low-risk (36%), 
intermediate-risk 
(14%) and high-risk 
(50%) (previous 
intravesical treatment 
not specified) 
0% MMC: 10.5 
 
EDMA MMC: 
14.5 
MMC: 8 once weekly 
40 mg 50 ml water for 
120 mins  
EMDA MMC: 8 once 
weekly 40 mg MMC 
(15 mA) for 20 mins 
NA CR: MMC: 
 41.6%, EMDA MMC: 
40% 
 
RFS: MMC: 15.4%, 
EMDA MMC: 
 26.7  
NA 91 
CR, complete response; DFS, disease-free survival; EMDA, electromotive drug administration; MMC, mitomycin C; NA, not applicable; NMIBC, non-muscle-invasive bladder 591 
cancer; RCT, randomized control trial; RITE, radiofrequency induced thermochemotherapeutic effect; RFS, recurrence-free survival; TURBT, transurethral resection of 592 
bladder tumour. 593 
 594 
 595 
 596 
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Table 7: Adverse events in NMIBC treated with EMDA MMC monotherapy 597 
 598 
 599 
EMDA, electromotive drug administration; MMC, mitomycin C; NA, not applicable; NMIBC, non-muscle-invasive bladder cancer; NR, not reported; UTI, urinary tract infection. 600 
Note: Total percentages have been calculated by the sum of patients observing a specific adverse event divided by the total number of patients of each study where the specific adverse event 601 
is report   602 
 603 
 604 
  605 
First author  Number of 
patients 
Complete treatment 
(%)  
Grade ≥ 3 
adverse events 
(%) 
Haematuria (%) UTI or sepsis 
(%) 
Suprapubic pain (%) Non-infective 
cystitis (%) 
Bladder spasm or 
urgency(%)  
Allergic reaction 
(%) 
Refs 
Di Stasi et al., 2003  36 92 8 8 19 0 36 0 8 94 
Riedi et al., 1998  22 86 NR 5 5 18 9 63 0 95 
Brausi et al., 1998  15 93 NR 0 0 0 13 0 13 91 
Total 73 90.4% 8.3% 12.7% 11.0% 5.5% 23.3% 19.2% 5.5% NA 
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 Table 8: Estimated end-user cost of intravesical device-assisted therapies for bladder cancer  606 
Factor  Synergo HIVEC Unithermia EMDA 
Estimated end-user cost (£) of disposables 
per treatment  
650 195 150 260 
Number of treatments  6 once weeklyinduction plus 
maintenance of  1 treatment every 6 
weeks for year one (6 treatments) and  
1 treatment every 8 weeks for year 
two (7 treatments)=  19 treatments 
total47 
 
6 weekly induction plus 3 weekly at 3, 
6, and 12 months, 15 treatments 
total31 
6 weekly plus 6 monthly treatments, 12 
treatments total 32 
 
6 weekly plus 9 monthly treatments, 15 
treatments total 
6 weekly plus 3 weekly 
instillations at 3 and 6 months, 
12 treatments total33, 83 
BCG and EMDA: 9 weekly treatments 
(2  BCG treatments plus1  EMDA 
treatments repeated 3 times) plus 9 
monthly (2 X EMDA plus 1 X BCG 
repeated 3 times), 9 EMDA plus 9 BCG 
total93 
 
EMDA: 6 weekly plus 10 monthly 
EMDA, 16 treatments total94 
Time for each treatment session (min) 30 plus 30 60 50 30 
Estimated end-user cost of disposables for 6 
weekly induction treatment 
3,900 1,170 900 BCG and EMDA: 780 
EMDA: 1,560 
Total cost of MMC for induction (£80/unit) ‡ 480 480 480 BCG and EMDA: 240 
EMDA: 480 
Total cost of BCG for induction (£120/unit) ‡ NA  NA NA BCG and EMDA: 720 
Estimated total end-user cost for 6 weekly 
induction treatment  
4,380 1,650 1,380 BCG and EMDA: 1,740 
EMDA: 2,040 
Estimated end-user cost of disposables for 
induction and maintenance treatment 
9,750-12,350 2,340-2,925 1,800 BCG and EMDA: 2,340  
EMDA: 4,160 
Total cost of MMC for induction and 
maintenance (£80/unit) ‡ 
1,200-1,520 960-1,200 960 BCG and EMDA: 720  
EMDA: 1,280 
Total cost of BCG for induction and 
maintenance (£120/unit) ‡ 
NA NA NA BCG and EMDA: 1,080 
Estimated end-user cost for induction and 
maintenance treatment 
10,950-13,870 3,300-4,125 2,760 BCG and EMDA: 4,140 
EMDA: 5,440 
 ‡ Prices according to the British National Formulary 607 
EMDA, electromotive drug administration; MMC, mitomycin C; NA, not applicable. 608 
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Figures 609 
Figure 1: Schematic diagram of the Synergo system. The Synergo system comprise of a radiofrequency generator which delivers radio-frequency energy at 915 MHz, a drug 610 
circulation unit which promotes the circulation of chemotherapy from the device to the bladder within a close system and vice versa and a computer system with application 611 
specific software. The specialised triple lumen silicon catheter has a lumen to fill the balloon at the catheter tip, an inflow and outflow channel. At the distal end of the catheter, 612 
thermocouples are on contact with the bladder wall for accurate temperature measurement as well as the miniaturised antenna which delivers radiofrequency to the bladder 613 
wall.  Reproduced with permission  614 
 615 
30 
 
Figure 2: Schematic diagram of the Combat BRS system. The Combat BRS system uses an aluminium heat exchange to allow efficient heat transfer. Circulating 616 
chemotherapy is then recirculated within a close system at a rate of 200 ml per minute. The triple lumen catheter comprises a lumen to fill the balloon at the catheter tip, an 617 
inflow and outflow channel, as well as a temperature probe.   Reproduced with permission  618 
 619 
 620 
 621 
 622 
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Figure 3: Schematic diagram of the EMDA system. The EMDA system comprise of a battery- powered generator, a specialised triple lumen catheter with a lumen for the 623 
catheter tip balloon, inflow and outflow channel as well as an active electrode at the tip of the catheter. Two dispersive electrodes a positioned at the suprapubic area which 624 
acts as dispersive ground electrodes.    Reproduced with permission  625 
 626 
 627 
 628 
 629 
 630 
 631 
 632 
 633 
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Figure 4: GemRIS intravesical gemcitabine depot delivery system. The GemRIS system comprise of a 5 cm dual silicon tube which a Gemcitabine core to allow continuous 634 
drug release over days. Nitinol wiring within the silicon tube preforms the device into a ‘pretzel’ like shape preventing the risk of expulsion from the bladder. Reproduced with 635 
permission  636 
 637 
 638 
 639 
 640 
 641 
 642 
 643 
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Appendix 644 
Supplementary Table 3: Comparison of reported adverse events in RCTs between RITE, BCG and MMC alone  645 
BCG RITE MMC alone Refs 
NA Increased pain, 
bladder wall 
erythema 
No difference in 
dysuria, haematuria, 
urethral stenosis, or 
allergy 
No difference in 
dysuria, 
haematuria, 
urethral stenosis, 
allergy 
 
60 
Increased urinary 
frequency, nocturia, 
incontinence, 
haematuria, fever, 
fatigue, arthralgia, 
and cystitis 
No difference in 
urinary tract 
infection or residual 
urine volume  
Increased bladder 
pain, bladder spasm, 
catheterisation 
difficulty, urethral 
stricture, bladder 
wall erythema, and 
allergic reaction 
No difference in 
urinary tract 
infection or residual 
urine volume 
NA 53 
MMC, mitomycin C; RCT, randomized control trial; RITE, radiofrequency-induced thermochemotherapeutic effect. 646 
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